{"entity":{"id":"michael-boyer","kind":"person","name":"Michael Boyer","aka":[],"tldr":"Thoracic medical oncologist who has been chief executive of Chris O'Brien Lifehouse, Sydney's not-for-profit cancer hospital, since 2023.","summary":"Professor Michael Boyer AM is Chief Executive Officer of Chris O'Brien Lifehouse, a not-for-profit comprehensive cancer hospital in Sydney, and Conjoint Chair of Medical Oncology (Thoracic Oncology). A medical oncologist for more than 20 years specialising in thoracic and head and neck cancers, he was appointed Chief Clinical Officer at Lifehouse in 2011 and Chief Executive Officer in 2023, and also sits on its Board of Directors. He was previously director of the Sydney Cancer Centre and area director of Cancer Services for the Sydney South West Area Health Service.","asOf":"2026-09-10","links":[{"label":"Source: Lifehouse our people page","url":"https://www.mylifehouse.org.au/about-us/our-people/"}],"tags":["leadership","clinician-scientist","thoracic-oncology"],"related":[],"cancers":["nsclc","sclc","head-and-neck","mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["chris-obrien-lifehouse"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer of Chris O'Brien Lifehouse","institutionId":"chris-obrien-lifehouse","specialisms":["Medical oncology","Thoracic cancers","Head and neck cancer","Clinical trials"],"profiles":[{"label":"Institution profile","url":"https://www.mylifehouse.org.au/team/michael-boyer/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Boyer+MJ%5BAuthor%5D+lung"}],"papers":[{"title":"Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study","journal":"Journal of Clinical Oncology","year":2021,"doi":"10.1200/jco.20.03579"},{"title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","journal":"The Lancet Oncology","year":2017,"doi":"10.1016/s1470-2045(17)30621-6"},{"title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","journal":"Annals of Oncology","year":2021,"doi":"10.1016/j.annonc.2021.04.008"}],"orcid":"0000-0002-0452-2987"},"route":"/people/michael-boyer/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"institution":[{"id":"chris-obrien-lifehouse","kind":"institution","name":"Chris O'Brien Lifehouse","route":"/institutions/chris-obrien-lifehouse/"}]}}